Summary
Genomic fusions of anaplastic lymphoma kinase (ALK) are a well-established therapeutic target in non-small-cell lung cancer (NSCLC). Although various ALK fusion variants have been identified in NSCLC, their responses to ALK tyrosine-kinase inhibitors (TKIs) are heterogeneous. We report the case of a 71-year-old female patient diagnosed with lung adenocarcinoma with liver metastases. A novel CTNND1 (exon 14)-ALK (exon 20) fusion was identified from the biopsy sample by next-generation sequencing (NGS) and validated by immunohistochemistry (IHC) staining. Alectinib was administered, and the patient soon achieved partial response (PR). The progression-free survival (PFS) exceeded 15 months as of January 25, 2022. Our findings expand the spectrum of ALK rearrangements and provide a potential treatment option for lung adenocarcinoma patients with CTNND1-ALK fusions.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Availability of data and materials
Not applicable.
References
Solomon B, Varella-Garcia M, Camidge DR (2009) ALK gene rearrangements: A new therapeutic target in a molecularly defined subset of non-small cell lung cancer. J Thorac Oncol 4:1450–1454. https://doi.org/10.1097/JTO.0b013e3181c4dedb
Recondo G, Facchinetti F, Olaussen KA, Besse B, Friboulet L (2018) Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI? Nat Rev Clin Oncol 15:694–708. https://doi.org/10.1038/s41571-018-0081-4
Yoshida T, Oya Y, Tanaka K, Shimizu J, Horio Y, Kuroda H, Sakao Y, Hida T, Yatabe Y (2016) Differential crizotinib response duration among ALK fusion variants in ALK-positive non-small-cell lung cancer. J Clin Oncol 34:3383–3389. https://doi.org/10.1200/JCO.2015.65.8732
Mok T, Camidge DR, Gadgeel SM, Rosell R, Dziadziuszko R, Kim DW, Pérol M, Ou SHI, Ahn JS, Shaw AT, Bordogna W, Smoljanović V, Hilton M, Ruf T, Noé J, Peters S (2020) Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study. Ann Oncol 31:1056–1064. https://doi.org/10.1016/j.annonc.2020.04.478
Camidge DR, Dziadziuszko R, Peters S et al (2019) Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non–Small Cell Lung Cancer in the Global Phase III ALEX Study. J Thorac Oncol 14(7):1233–1243. doi:https://doi.org/10.1016/j.jtho.2019.03.007
Sun K, Nie L, Nong L, Cheng Y (2021) Primary resistance to alectinib in a patient with STRN-ALK-positive non-small cell lung cancer: A case report. Thorac Cancer 12(12):1927–1930. doi:https://doi.org/10.1111/1759-7714.13983
Iwahara T, Fujimoto J, Wen D et al (1997) Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system. Oncogene 14(4):439–449. doi:https://doi.org/10.1038/sj.onc.1200849
Hallberg B, Palmer RH (2016) The role of the ALK receptor in cancer biology. Ann Oncol 27(Supplement 3):iii4–iii15. doi:https://doi.org/10.1093/annonc/mdw301
Chiarle R, Voena C, Ambrogio C, Piva R, Inghirami G (2008) The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer 8(1):11–23. doi:https://doi.org/10.1038/nrc2291
Kong X, Pan P, Sun H et al (2019) Drug Discovery Targeting Anaplastic Lymphoma Kinase (ALK). J Med Chem 62(24):10927–10954. doi:https://doi.org/10.1021/acs.jmedchem.9b00446
Noé J, Lovejoy A, Ou SHI, Yaung SJ, Bordogna W, Klass DM, Cummings CA, Shaw AT (2020) ALK Mutation Status Before and After Alectinib Treatment in Locally Advanced or Metastatic ALK-Positive NSCLC: Pooled Analysis of Two Prospective Trials. J Thorac Oncol 15:601–608. https://doi.org/10.1016/j.jtho.2019.10.015
Katayama R, Friboulet L, Koike S et al (2014) Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib. Clin Cancer Res 20(22):5686–5696. doi:https://doi.org/10.1158/1078-0432.CCR-14-1511
Lin JJ, Zhu VW, Schoenfeld AJ et al (2018) Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLC. J Thorac Oncol 13(10):1530–1538. doi:https://doi.org/10.1016/j.jtho.2018.06.005
Acknowledgements
The authors thank Chuang Qi, Yaqin Liu, Ran Ding, Guanghua Lu and Wanglong Deng from Jiangsu Simcere Diagnostics for the kindly assistance.
Funding
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Author information
Authors and Affiliations
Contributions
Conception/Design: Yuanjian Cheng, Xiang Tian, Qiong Liao. Provision of study material or patients: Xiang Tian, Qidong Yang. Collection of data: Xiang Tian, Qiong Liao. Data analysis and interpretation: Qidong Yang, Lin Chen. Manuscript writing: Xiang Tian, Qidong Yang, Mingzhe Xiao, Lin Chen. Final approval of manuscript: Yuanjian Cheng, Qiong Liao, Mingzhe Xiao.
Corresponding author
Ethics declarations
Ethics approval and consent to participate
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Consent for publication
Informed consent was obtained from the patient.
Conflict of interest
The authors declare that they have no conflict of interest.
Disclosure of potential conflicts of interest
The authors declare that they have no conflict of interest.
Research involving Human Participants and/or Animals
Not applicable.
Informed consent
Informed consent was obtained from the patient.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Tian, X., Liao, Q., Yang, Q. et al. A novel alectinib-sensitive CTNND1-ALK fusion in a lung adenocarcinoma patient: a case report. Invest New Drugs 40, 850–853 (2022). https://doi.org/10.1007/s10637-022-01245-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10637-022-01245-3